OncoMatch/Triple-Negative Breast Cancer (TNBC)/PD-L1 (CD274)
Triple-Negative Breast Cancer (TNBC)PD-L1 (CD274) Clinical Trials
PD-L1 CPS ≥10 is required for first-line pembrolizumab plus chemotherapy in locally recurrent unresectable or metastatic TNBC (KEYNOTE-355); early-stage high-risk TNBC uses pembrolizumab with neoadjuvant chemotherapy followed by adjuvant pembrolizumab regardless of PD-L1 status (KEYNOTE-522). Trials explore novel checkpoint combinations, LAG-3/TIM-3 inhibitors, and IO strategies across PD-L1 expression levels in metastatic and early-stage TNBC.
Top recruiting PD-L1 (CD274) Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Sun Yat-sen University
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
Fudan University
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
Fudan University
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Fundacio Clinic Barcelona